Cue Biopharma is trading at $29.02 (6.2% down) as the stock extends a pullback following a volatile rally driven by a new licensing deal and financing momentum.
- The stock recently experienced a nearly 100% after-hours surge fueled by a $30 million private placement, the acquisition of a clinical-stage drug candidate, and the appointment of a new CEO.
- Current downward pressure is attributed to profit-taking and investor concerns regarding potential dilution following the recent financing activities.